ReviewCancer communications (London, England)2022
The diagnosis, classification, and treatment of sarcoma in this era of artificial intelligence and immunotherapy.
Review in Cancer communications (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Integrating radiomics, artificial intelligence, and molecular signatures in bone and soft tissue tumors: advances in diagnosis and prognostication.Frontiers in oncology · 2025Pooled it
- Radiomics: Current Applications and Future Directions.MedComm · 2026Review
- Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Automated detection of primary soft tissue sarcomas of the extremities using artificial intelligence and ChatGPT.Frontiers in oncology · 2026Article
- Focused Ultrasound for Sarcomas: A Narrative Review.Current oncology (Toronto, Ont.) · 2025Review
- Identification of novel diagnostic and prognostic microRNAs in sarcoma on TCGA dataset: bioinformatics and machine learning approach.Scientific reports · 2025Article
- Malignant fibrous histiocytoma of the heart: a rare case report of an aggressive cardiac sarcoma mimicking myxoma.European heart journal. Case reports · 2025Article
- Integrated Transcriptomic Landscape and Deep Learning Based Survival Prediction in Uterine Sarcomas.Cancer research and treatment · 2025Article
- Diagnostic utility of MRI-based convolutional neural networks in soft tissue sarcomas: a mini-review.Frontiers in oncology · 2025Review
- Utility of artificial intelligence in a binary classification of soft tissue tumors.Journal of pathology informatics · 2024Article
- Analysis of metastasis‑related risk factors and clinical relevance in adult soft‑tissue sarcoma.Oncology letters · 2024Article
- Cold and hot tumors: from molecular mechanisms to targeted therapy.Signal transduction and targeted therapy · 2024Review
- Self-healing hydrogels for enhancing chemotherapy drug efficacy: Advancements in anti-sarcoma and carcinoma therapies and clinical trial feasibility.Cancer pathogenesis and therapy · 2024Review
- Deep learning on tertiary lymphoid structures in hematoxylin-eosin predicts cancer prognosis and immunotherapy response.NPJ precision oncology · 2024Article
- The impact of radiomics in the management of soft tissue sarcoma.Discover oncology · 2024Review
- Review
- Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies.iMeta · 2024Review
- Staging Systems and Nomograms for Soft Tissue Sarcoma.Current oncology (Toronto, Ont.) · 2023Review
- Editorial: Efficacy, safety and biomarkers of novel therapeutics and regimens in the peri-operative setting of bone and soft tissue sarcoma.Frontiers in surgery · 2023Article
- Editorial: Unravelling the sarcoma microenvironment: Impact of the genomic landscape on molecular signaling, immunosuppression, and treatment resistance.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Soft-tissue sarcomas (STS) represent a group of rare and heterogeneous tumors associated with several challenges, including incorrect or late diagnosis, the lack of clinical expertise, and limited therapeutic options. Digital pathology and radiomics represent transformative technologies that appear promising for improving the accuracy of cancer diagnosis, characterization and monitoring. Herein, we review the potential role of the application of digital pathology and radiomics in managing patients with STS. We have particularly described the main results and the limits of the studies using radiomics to refine diagnosis or predict the outcome of patients with soft-tissue sarcomas. We also discussed the current limitation of implementing radiomics in routine settings. Standard management approaches for STS have not improved since the early 1970s. Immunotherapy has revolutionized cancer treatment; nonetheless, immuno-oncology agents have not yet been approved for patients with STS. However, several lines of evidence indicate that immunotherapy may represent an efficient therapeutic strategy for this group of diseases. Thus, we emphasized the remarkable potential of immunotherapy in sarcoma treatment by focusing on recent data regarding the immune landscape of these tumors. We have particularly emphasized the fact that the development of immunotherapy for sarcomas is not an aspect of histology (except for alveolar soft-part sarcoma) but rather that of the tumor microenvironment. Future studies investigating immunotherapy strategies in sarcomas should incorporate at least the presence of tertiary lymphoid structures as a stratification factor in their design, besides including a strong translational program that will allow for a better understanding of the determinants involved in sensitivity and treatment resistance to immune-oncology agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.